attachment

Answer these questions for bds 1st board exam of pharmacology Kathmandu University

Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
I now have excellent source material. Let me compile the full comprehensive answers.

BDS 1st Year Pharmacology - Haematopoietics & Related Topics

Kathmandu University Board Exam Answers


Q1. Classify Anticoagulants with Examples. Write the Mechanism of Action and Uses of Heparin. [3+1+1 = 5]

Classification of Anticoagulants

A. Parenteral Anticoagulants
  1. Unfractionated Heparin (UFH) - e.g., Heparin sodium
  2. Low Molecular Weight Heparins (LMWH) - e.g., Enoxaparin, Dalteparin
  3. Fondaparinux - synthetic pentasaccharide
  4. Direct Thrombin Inhibitors - Bivalirudin, Argatroban, Lepirudin
  5. Factor Xa Inhibitors (parenteral) - Fondaparinux
B. Oral Anticoagulants
  1. Vitamin K Antagonists - Warfarin, Acenocoumarol
  2. Direct Oral Anticoagulants (DOACs)
    • Direct thrombin inhibitors: Dabigatran
    • Factor Xa inhibitors: Rivaroxaban, Apixaban, Edoxaban

Mechanism of Action of Heparin

Heparin is a strongly acidic, straight-chain anionic glycosaminoglycan (mucopolysaccharide) extracted from porcine intestinal mucosa.
MOA:
  • Heparin binds to Antithrombin III (AT-III), causing a conformational change in AT-III that accelerates its inhibitory action by 1000-fold
  • The heparin-AT-III complex inhibits thrombin (Factor IIa) and Factor Xa, and to a lesser extent Factors IXa, XIa, XIIa
  • This prevents conversion of fibrinogen to fibrin, thus blocking clot formation
  • Heparin also releases lipoprotein lipase from endothelial surfaces (responsible for its lipid-clearing effect)
  • UFH requires a minimum chain length of 18 saccharide units to bridge AT-III and thrombin simultaneously
- Lippincott Illustrated Reviews Pharmacology, p. 449-450

Uses of Heparin

  1. Deep vein thrombosis (DVT) - treatment and prophylaxis
  2. Pulmonary embolism (PE)
  3. Acute coronary syndromes (unstable angina, STEMI) - alongside thrombolytics
  4. Cardiopulmonary bypass surgery
  5. Prevention of clotting in IV lines, dialysis circuits
  6. Disseminated intravascular coagulation (DIC)
  7. Bridging therapy when transitioning from oral anticoagulants
Monitoring: aPTT (activated partial thromboplastin time) - target 1.5-2.5x normal
Antidote: Protamine sulfate

Q2. MOA of Aspirin as an Anticoagulant with its Two Adverse Effects [2+3 = 5]

Mechanism of Action of Aspirin as an Antiplatelet Agent

Aspirin is the most widely used antiplatelet drug worldwide.
  1. Platelet activation by thrombin, collagen, and ADP activates platelet membrane phospholipases, which liberate arachidonic acid from membrane phospholipids
  2. Arachidonic acid is converted to Prostaglandin H2 by Cyclooxygenase-1 (COX-1)
  3. Prostaglandin H2 is further metabolized to Thromboxane A2 (TXA2), which promotes platelet aggregation essential for hemostatic plug formation
  4. Aspirin irreversibly acetylates a serine residue on the active site of COX-1, permanently inactivating the enzyme
  5. This shifts the balance from TXA2 (pro-aggregatory) toward Prostacyclin (PGI2) (anti-aggregatory), produced in endothelial cells
  6. Since platelets have no nucleus, they cannot synthesize new COX; therefore the effect lasts the entire platelet lifespan (~7-10 days)
  7. Endothelial cells DO have nuclei and can regenerate COX, so prostacyclin production recovers
At low doses (75-150 mg): Selectively inhibits platelet COX-1 with minimal effect on endothelial COX-2 - hence LOW DOSE ASPIRIN is used as an antiplatelet
- Lippincott Illustrated Reviews Pharmacology, p. 438-439

Two Major Adverse Effects of Aspirin:

  1. GI disturbances / Peptic ulcer / GI Bleeding
    • Aspirin inhibits COX-1 in gastric mucosa, reducing protective prostaglandin (PGE2) synthesis
    • Results in erosion of gastric mucosa, epigastric pain, nausea, and GI bleeding
    • Most common adverse effect; use of PPI or misoprostol reduces this risk
  2. Bleeding tendency / Hemorrhage
    • Due to irreversible inhibition of platelet function for the entire platelet lifespan
    • Manifests as prolonged bleeding time, easy bruising, surgical bleeding
    • Contraindicated pre-operatively (stop 7-10 days before surgery)
    • Can cause Reye's syndrome in children with viral illness (hepatic failure + encephalopathy)
Other important effects: Bronchospasm, angioedema, salicylism at higher doses

Q3. List Drugs Used in Cancer. Write Down the Common Adverse Effects of Anticancer Drugs. [2+3 = 5]

Classification of Anticancer Drugs (with examples)

ClassExample
Alkylating agentsCyclophosphamide, Busulfan, Cisplatin
AntimetabolitesMethotrexate, 5-Fluorouracil, 6-Mercaptopurine
Vinca alkaloidsVincristine, Vinblastine
TaxanesPaclitaxel, Docetaxel
Topoisomerase inhibitorsIrinotecan, Etoposide
Antibiotics (cytotoxic)Doxorubicin, Bleomycin
Hormonal agentsTamoxifen, Flutamide
Targeted therapy/Monoclonal AbImatinib, Trastuzumab, Rituximab
Platinum compoundsCisplatin, Carboplatin

Common Adverse Effects of Anticancer Drugs

Anticancer drugs preferentially affect rapidly dividing cells (both malignant and normal). The common adverse effects are:
  1. Myelosuppression (Bone Marrow Suppression)
    • Leukopenia (infection risk), thrombocytopenia (bleeding), anemia
    • Most serious and dose-limiting toxicity for most agents
  2. GI Toxicity
    • Nausea, vomiting (especially cisplatin - managed with ondansetron)
    • Mucositis (oral ulcers), diarrhea, anorexia
  3. Alopecia (Hair Loss)
    • Due to destruction of rapidly dividing hair follicle cells
    • Usually reversible after stopping therapy
  4. Reproductive Toxicity / Gonadal Suppression
    • Infertility, teratogenicity, amenorrhea
  5. Immunosuppression
    • Increased susceptibility to opportunistic infections
  6. Organ-specific toxicities:
    • Cardiotoxicity: Doxorubicin (dilated cardiomyopathy)
    • Nephrotoxicity: Cisplatin
    • Pulmonary fibrosis: Bleomycin
    • Peripheral neuropathy: Vincristine, Paclitaxel
    • Hemorrhagic cystitis: Cyclophosphamide (prevented by Mesna)
  7. Secondary malignancies - risk of leukemia with long-term alkylating agents

Q4. Classify Antimalarial Drugs. Write the Uses and Adverse Effects of Chloroquine. Give the Mode of Action and Toxicities of Mefloquine. [1+1+2+1 = 5]

Classification of Antimalarial Drugs

A. Blood Schizonticides (act on erythrocytic stage):
  • 4-Aminoquinolines: Chloroquine, Amodiaquine, Piperaquine
  • Quinoline methanol: Mefloquine, Quinine
  • Artemisinin derivatives: Artesunate, Artemether, Dihydroartemisinin
  • Antifolates: Pyrimethamine, Proguanil
B. Tissue Schizonticides (act on hepatic stage):
  • 8-Aminoquinolines: Primaquine, Tafenoquine (radical cure of P. vivax)
C. Gametocides:
  • Primaquine (for P. falciparum gametocytes)
  • Chloroquine (for P. vivax, P. ovale gametocytes)
D. Causal Prophylactics:
  • Primaquine, Proguanil

Chloroquine - Uses and Adverse Effects

Uses:
  1. Drug of choice for uncomplicated P. vivax and P. ovale malaria (given WITH primaquine for radical cure)
  2. Treatment of sensitive P. falciparum malaria (resistance widespread)
  3. Extra-intestinal amoebiasis (hepatic amoebiasis)
  4. Rheumatoid arthritis and SLE (as disease-modifying agent)
  5. Prophylaxis in chloroquine-sensitive regions
Adverse Effects:
  • GI: nausea, vomiting, abdominal pain (take with food)
  • Retinopathy (cumulative dose-dependent) - most feared long-term toxicity; requires annual eye screening
  • Pruritus (especially in African patients)
  • CNS: headache, dizziness, insomnia
  • Cardiotoxicity - QT prolongation at high doses
  • Rare: agranulocytosis, bleaching of hair, exacerbation of psoriasis

Mefloquine - Mode of Action and Toxicities

Mode of Action:
  • Mefloquine is a quinoline methanol compound
  • Exact mechanism not fully established, but similar to chloroquine: believed to interfere with heme detoxification within the parasite food vacuole
  • Mefloquine accumulates in parasite food vacuoles and is thought to form toxic complexes with free heme, disrupting parasite membrane integrity
  • Active against blood schizonts of all four species
  • Can be combined with artesunate (artemisinin-based combination therapy)
Toxicities:
  1. CNS toxicity - most important; the (-) enantiomer is particularly associated with CNS adverse effects
    • Dizziness, vertigo, ataxia
    • Vivid dreams, nightmares, insomnia
    • Neuropsychiatric effects - anxiety, depression, hallucinations, psychosis (rare but serious; black box warning)
  2. GI disturbances - nausea, vomiting, diarrhea
  3. Bradycardia and QT prolongation - avoid with other drugs prolonging QT
  4. Contraindicated in: psychiatric disorders, seizure history, pilots/divers
- Goodman & Gilman's Pharmacological Basis of Therapeutics

Q5. Classify Drugs Used in Therapy of Thrombogenic/Thromboembolic Disorders with One Example Each. List Drugs Used in Therapy of Megaloblastic Anaemia with or without Neurological Involvement. [3+2 = 5]

Classification - Drugs for Thrombogenic/Thromboembolic Disorders

1. Anticoagulants
  • Parenteral: Heparin (UFH), Enoxaparin (LMWH)
  • Oral: Warfarin; Direct oral: Dabigatran, Rivaroxaban
2. Antiplatelet Agents
  • COX inhibitors: Aspirin
  • P2Y12 inhibitors: Clopidogrel, Ticagrelor
  • PDE inhibitors: Dipyridamole
  • GP IIb/IIIa inhibitors: Abciximab
3. Thrombolytics (Fibrinolytics)
  • Streptokinase, Alteplase (tPA), Urokinase, Tenecteplase
4. Antifibrinolytics (to control excessive clot dissolution)
  • Tranexamic acid, Aminocaproic acid

Drugs for Megaloblastic Anaemia

Megaloblastic anaemia is characterized by abnormally large RBCs (elevated MCV), caused by impaired DNA synthesis due to deficiency of Vitamin B12 or Folic Acid.
Without neurological involvement (Folate deficiency only):
  • Folic acid (folate) - oral supplementation
    • Given orally, rapidly absorbed in jejunum
    • Causes: inadequate intake, increased demand (pregnancy), alcoholism, methotrexate use, malabsorption
    • Dose: 5 mg/day orally
With neurological involvement (Vitamin B12 deficiency / Pernicious Anaemia):
  • Cyanocobalamin or Hydroxocobalamin (Vitamin B12)
    • Given IM (preferred in pernicious anaemia due to lack of intrinsic factor)
    • Hydroxocobalamin IM is preferred - highly protein bound, maintains longer plasma levels
    • In dietary deficiency: oral cyanocobalamin
    • In pernicious anaemia: IM therapy must be continued FOR LIFE
CRITICAL POINT for exams: Empiric treatment of megaloblastic anaemia must NEVER use folic acid alone. Always use BOTH folic acid + vitamin B12 unless confirmed by investigations. Giving folic acid alone will correct the anaemia but MASK the B12 deficiency, allowing neurological damage (subacute combined degeneration of spinal cord) to progress irreversibly.
- Lippincott Illustrated Reviews Pharmacology, p. 1479-1481

Q6. Classify Antihistamines. Write Down the Pharmacological Management of Chronic Obstructive Pulmonary Disease (COPD). Write Down Their Uses and Adverse Effects. [3+3 = 6]

Classification of Antihistamines

H1-Antihistamines:
First Generation (Classical/Sedating):
DrugClass
DiphenhydramineEthanolamine
ChlorpheniramineAlkylamine
PromethazinePhenothiazine
CyclizinePiperazine
CyproheptadinePiperidine
Second Generation (Non-sedating):
  • Cetirizine, Loratadine, Fexofenadine, Desloratadine, Levocetirizine, Bilastine
H2-Antihistamines:
  • Ranitidine, Famotidine, Cimetidine (used for peptic ulcer, GERD)
H3-Antihistamines (experimental):
  • Thioperamide (CNS research)

Pharmacological Management of COPD

COPD is characterized by persistent, progressive airflow limitation due to chronic bronchitis and/or emphysema.
Step-wise Management:
1. Bronchodilators (cornerstone of COPD therapy)
  • Short-acting Beta-2 agonists (SABA): Salbutamol (albuterol), Terbutaline - for rescue/PRN use
  • Long-acting Beta-2 agonists (LABA): Salmeterol, Formoterol, Indacaterol - for maintenance
  • Short-acting muscarinic antagonists (SAMA): Ipratropium bromide
  • Long-acting muscarinic antagonists (LAMA): Tiotropium, Umeclidinium (preferred maintenance bronchodilator in COPD)
  • Methylxanthines: Theophylline (bronchodilator + anti-inflammatory; narrow therapeutic index)
2. Inhaled Corticosteroids (ICS)
  • Budesonide, Fluticasone, Beclomethasone
  • Used in combination with LABA (e.g., Salmeterol/Fluticasone)
  • Reserved for patients with frequent exacerbations or concurrent asthma
3. Combination Therapy
  • LABA + LAMA (dual bronchodilation) - e.g., Indacaterol/Glycopyrronium
  • LABA + ICS - e.g., Formoterol/Budesonide
  • Triple therapy: LABA + LAMA + ICS for severe disease
4. Phosphodiesterase-4 Inhibitor
  • Roflumilast - reduces exacerbation frequency; used as add-on therapy in severe COPD with chronic bronchitis
5. Mucolytics
  • N-acetylcysteine, Carbocisteine - reduce mucus viscosity
6. Oxygen therapy - for severe COPD (PaO2 < 55 mmHg)
7. Antibiotics - during acute exacerbations (Amoxicillin, Doxycycline, Azithromycin)

Uses of Antihistamines

H1-Antihistamines:
  1. Allergic conditions - allergic rhinitis, urticaria, angioedema, atopic dermatitis
  2. Anaphylaxis (adjunct to epinephrine)
  3. Motion sickness - Promethazine, Cyclizine, Meclizine
  4. Nausea and vomiting - Promethazine (antiemetic)
  5. Pruritus - Chlorpheniramine, Cetirizine
  6. Sedation/premedication - 1st generation (e.g., Promethazine)
  7. Common cold - 1st generation for symptomatic relief
  8. Antitussive (cough suppression) - Diphenhydramine
H2-Antihistamines:
  1. Peptic ulcer disease
  2. GERD
  3. Zollinger-Ellison syndrome

Adverse Effects of Antihistamines

First Generation (CNS-penetrating):
  1. Sedation and drowsiness - most common (due to H1 blockade in CNS)
  2. Impaired psychomotor performance - avoid driving, operating machinery
  3. Anticholinergic effects:
    • Dry mouth, blurred vision, urinary retention, constipation
    • Tachycardia
  4. Paradoxical CNS excitation in children - restlessness, insomnia
  5. Appetite stimulation and weight gain (Cyproheptadine)
  6. GI: nausea, epigastric discomfort
  7. Potentiates CNS depressants (alcohol, sedatives)
Second Generation:
  1. Minimal sedation (do not cross BBB well)
  2. Rare cardiotoxicity - QT prolongation (mostly with old agents like terfenadine - now withdrawn)
  3. Headache, dry mouth (mild)
H2-Antihistamines (Cimetidine specifically):
  1. Gynecomastia, impotence (anti-androgenic effect)
  2. Drug interactions (inhibits CYP450)

Summary of Short Notes (from the list on paper):

1. Why Primaquine should be given WITH Chloroquine in P. vivax malaria:
  • Chloroquine kills erythrocytic (blood) stage schizonts - eliminates the acute attack
  • But it has NO activity against hypnozoites (dormant liver stage of P. vivax)
  • Primaquine is the only drug that kills hepatic hypnozoites (radical cure) and gametocytes
  • Together: Chloroquine (blood stage) + Primaquine (liver stage + gametocytes) = COMPLETE cure and prevention of relapse
  • Always check for G6PD deficiency before giving primaquine (can cause hemolytic anaemia)
2. Low-dose Aspirin: 75-150 mg/day - selectively inhibits platelet COX-1; used in IHD prophylaxis, prevention of TIA and stroke, post-MI, atrial fibrillation
3. Heparin: Rapid-acting injectable anticoagulant; acts via AT-III; monitored by aPTT; antidote = Protamine sulfate
4. Chloroquine: 4-aminoquinoline; drug of choice for P. vivax; also used in SLE, RA; retinopathy is feared chronic toxicity
5. Antihistamine (circled): H1 and H2 classification; 1st vs 2nd generation; sedation is main adverse effect of 1st generation
This is a shared conversation. Sign in to Orris to start your own chat.